Lundbeck starts clinical phase III program with Lu AF35700

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Sino BioPharm to Acquire LaNova Medicines for $950.9 M Deal

LaNova Medicines, which happens to be a cancer drugmaker...

Rheumatoid Arthritis Treatment with Genetic Link Adds Hope

Researchers at the University of Edinburgh have gone on...

Sleep Lean Reviews – Is It Effective for Weight Loss?

Sleep Lean is a dietary supplement formulated for people...

CDSCO Moves to Online Submission for CGTP Trial Applications

As part of its continued efforts to streamline operations...

H. Lundbeck A/S announced that the investigational compound Lu AF35700, a novel antipsychotic, is entering clinical phase III program.

Lundbeck is initiating the phase III program which is currently planned to consist of two pivotal trials. Two doses of Lu AF35700 (10 and 20 mg) will be tested in patients with treatment resistant schizophrenia. The primary endpoint is change from baseline to study week 10 in Positive and Negative Syndrome Scale (PANSS) total score. Additional endpoints include Clinical Global Impression — Severity of Illness (CGI-S) score and Personal and Social Performance Scale (PSP).

The first study is planned to enroll approximately 1,000 patients in approximately 15 countries including the U.S. and Canada and is expected to last around three years.

Lu AF35700 has been granted Fast Track designation in treatment resistant schizophrenia by FDA.

 

Latest stories

Related stories

Sino BioPharm to Acquire LaNova Medicines for $950.9 M Deal

LaNova Medicines, which happens to be a cancer drugmaker...

Rheumatoid Arthritis Treatment with Genetic Link Adds Hope

Researchers at the University of Edinburgh have gone on...

Sleep Lean Reviews – Is It Effective for Weight Loss?

Sleep Lean is a dietary supplement formulated for people...

CDSCO Moves to Online Submission for CGTP Trial Applications

As part of its continued efforts to streamline operations...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back